SCHEMBL18482255

SCHEMBL18482255

COC(C)(C)CCOC(C)(C)CCNC(=O)CCC(C)(C)OCCC(C)(C)SCc1cccc(C(=O)Nc2ccc(N3CCCCC3)cc2-c2cc(C(=O)NCc3cccc(C(F)(F)F)c3)ccn2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 1/20 0.48
BRAF P15056 5/20 0.35
KDM4E B2RXH2 1/20 0.35
RAF1 P04049 2/20 0.35
ROCK2 O75116 3/20 0.34
ROCK1 Q13464 3/20 0.34
GPR52 Q9Y2T5 1/20 0.34
TEK Q02763 1/20 0.34
CCR2 P41597 1/20 0.34
KCNH2 Q12809 1/20 0.34
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
SMYD2 Q9NRG4 1/20 0.32
PHGDH O43175 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18482335 0.95 SLC34A2 (0.48) SLC34A2BRAFKDM4ERAF1ROCK2
SCHEMBL18482337 0.91 SLC34A2 (0.57) SLC34A2BRAFKDM4ERAF1ROCK2
SCHEMBL18484278 0.91 SLC34A2 (0.46) SLC34A2BRAFRAF1KCNH2
SCHEMBL18482333 0.89 SLC34A2 (0.47) SLC34A2BRAFKDM4ERAF1ROCK2
SCHEMBL18482336 0.89 SLC34A2 (0.50) SLC34A2BRAFKDM4ERAF1ROCK2
SCHEMBL18482722 0.86 SLC34A2 (0.50) SLC34A2BRAFKDM4ERAF1ROCK2
SCHEMBL18482329 0.86 SLC34A2 (0.47) SLC34A2BRAFKDM4ERAF1TEK
SCHEMBL6002461 0.86 SLC34A2 (0.52) SLC34A2BRAFKDM4ERAF1ROCK2
SCHEMBL18482256 0.85 SLC34A2 (0.46) SLC34A2BRAFKDM4ERAF1KCNH2
SCHEMBL18482986 0.85 SLC34A2 (0.45) SLC34A2BRAFKDM4ERAF1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037010-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2017-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037010-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A2, SLC34A1, SLC10A2 SLC34A2 1/4885BRAF 3436/4885KDM4E 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.